No Data
Express News | CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer
CSTONE PHARMA-B (02616.HK) submitted a new indication application for Sugliatinib for the treatment of Phase III non-small cell lung cancer to the European Medicines Agency.
On March 24, Glonghui reported that CSTONE PHARMA-B (02616.HK) announced that the company has submitted a new indication application for Suglikumab to the European Medicines Agency (EMA) for the treatment of patients with unresectable stage III non-small cell lung cancer (NSCLC) who have not shown disease progression after concurrent or sequential chemoradiotherapy (CRT). This is the second indication that CSTONE PHARMA is advancing in the European market, following the EMA's first approval of this drug for first-line treatment of metastatic squamous and non-squamous NSCLC in 2024. If approved, Suglikumab will address the need in stage III non-small cell lung cancer.
CStone Pharmaceuticals Schedules Board Meeting to Approve 2024 Annual Results
CSTONE PHARMA-B: DATE OF BOARD MEETING
CSTONE PHARMA-B (02616): Advancing towards Pipeline 2.0, with significant potential for ROR1 ADC.
Cornerstone Pharmaceuticals is an innovative, research-driven Biomedical company focused on the R&D of anti-tumor drugs. As of February 2025, the company has successfully launched 4 Innovative Drugs and obtained approval for 16 new drug marketing applications (NDA and 9 indications).
Express News | CStone Submits Clinical Trial Application in Australia for Cs5001 (Ror1 ADC) in Combination With First-Line Standard-of-Care for Dlbcl
CStone Pharmaceuticals (HKG:2616) Not Doing Enough For Some Investors As Its Shares Slump 34%
